Evidence map›Paper›PMID 25193672›Full record

Observational studyThe British journal of ophthalmology2015

Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration.

Frank G Holz, Ramin Tadayoni, Stephen Beatty, Alan Berger, Matteo G Cereda, Rafael Cortez, Carel B Hoyng, Philip Hykin, Giovanni Staurenghi, Stephanie Heldner and 3 more

3 registry-linked trialsAbstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in The British journal of ophthalmology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 319 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
319citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01447043 completednot on this map

AURA Study: A Retrospective Non-interventional Study (NIS) to Assess the Effectiveness of Existing Anti vascUlar Endothelial Growth Factor (Anti VEGF) Treatment Regimens in Patients With Wet Age-related Macular Degeneration (wAMD)

TypeobservationalSponsorBayerRan2009 to 2012Enrolled2,609ConditionsOphthalmology, Macular DegenerationArmsRanibizumab
NCT05710471 phase4completednot on this mapstarted 2022, after this paper: background citation

Treatment of Recalcitrant Neovascular AMD Using Brolocizumab With a Novel Treat and Extend Protocol - a Randomized Controlled Prospective Study

TypeinterventionalSponsorThe University of Hong KongRan2022 to 2023Enrolled30ConditionsAge-Related Macular DegenerationArmsBrolucizumab, Aflibercept
NCT06022744 nanot yet recruitingnot on this mapstarted 2023, after this paper: background citation

An Exploratory Clinical Trial Evaluating LX109 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD)

TypeinterventionalSponsorShanghai General Hospital, Shanghai Jiao Tong University School of MedicineRan2023 to 2027Enrolled12ConditionsTo Evaluate the Safety and Tolerability of Intravitreal Injection of LX109 in Patients With nAMDArmsLX109
3 · Its place in the literature

Who cites it

319 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Ranibizumab biosimilars vs. reference Ranibizumab for neovascular age-related macular degeneration: a systematic review and meta-analysis.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2025
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Efficacy, durability, and safety of faricimab up to every 16 weeks in patients with neovascular age-related macular degeneration: 2-year results from the Japan subgroup of the phase III TENAYA trial.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2024
    Trial
  10. Trial
  11. Trial
  12. Trial
  13. To investigate treat and extend versus pro re nata regimen in neovascular age-related macular degeneration: results from the IDEM study.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2022
    Trial
  14. Trial
  15. Trial
  16. Trial
  17. One-year real-world data of intravitreal faricimab in patients with pre-treated neovascular age-related macular degeneration.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026
    Article
  18. Article
  19. Review
  20. Article

259 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Frank G HolzDepartment of Ophthalmology, University of Bonn, Bonn, Germany.
Ramin TadayoniDepartment of Ophthalmology, Hôpital Lariboisière, AP-HP, Université Paris 7-Sorbonne Paris Cité, France.
Stephen BeattyDepartment of Ophthalmology, Institute of Eye Surgery, Waterford, Ireland.
Alan BergerDepartment of Ophthalmology and Vision Sciences, University of Toronto, and St Michael's Hospital, Toronto, Canada.
Matteo G CeredaDepartment of Biomedical and Clinical Science Luigi Sacco, Luigi Sacco Hospital, University of Milan, Milan, Italy.
Rafael CortezCentro de Cirugia Oftalmologica, Caracas, Venezuela.
Carel B HoyngDepartment of Ophthalmology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.
Philip HykinNIHR Biomedical Centre for Research in Ophthalmology, Moorfields Eye Hospital, London, UK.
Giovanni StaurenghiDepartment of Biomedical and Clinical Science Luigi Sacco, Luigi Sacco Hospital, University of Milan, Milan, Italy.
Stephanie HeldnerBayer HealthCare Pharmaceuticals, Berlin, Germany.
Timon BogumilBayer HealthCare Pharmaceuticals, Montville, New Jersey, USA.
Theresa HeahBayer HealthCare Pharmaceuticals, Montville, New Jersey, USA.
Sobha SivaprasadNIHR Biomedical Centre for Research in Ophthalmology, Moorfields Eye Hospital, London, UK King's College Hospital, London, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimsReal-life anti-vascular endothelial growth factor (VEGF) therapy use in patients with wet age-related macular degeneration (wAMD) was assessed in a retrospective, observational study in Canada, France, Germany, Ireland, Italy, the Netherlands, UK and Venezuela.

methodsMedical records of patients with wAMD, who started ranibizumab treatment between 1 January 2009 and 31 August 2009, were evaluated. Data were collected until the end of treatment and/or monitoring or until 31 August 2011.

results2227 patients who received ≥1 anti-VEGF injection with a baseline visual acuity assessment and ≥1 postbaseline visual acuity assessment for the treated eye were evaluated. Visual acuity improved until about day 120; thereafter, visual acuity gains were not maintained. Mean change in visual acuity score from baseline to years 1 and 2 was +2.4 and +0.6 letters, respectively. Patients received a mean of 5.0 and 2.2 injections in the first and second year, respectively. There were substantial differences in visual outcomes and injection frequency between countries. More frequent visits and injections were associated with greater improvements in visual acuity.

conclusionsIn clinical practice, fewer injections are administered than in clinical trials. Anti-VEGF treatment resulted in an initial improvement in visual acuity; however, this was not maintained over time. TRIAL REGISTRATION NUMBER: NCT01447043.

Indexed as

AgedAged, 80 and overAngiogenesis InhibitorsAntibodies, Monoclonal, HumanizedCanadaEuropeFemaleHumansIntravitreal InjectionsMaleMiddle AgedRanibizumabRetreatmentRetrospective StudiesTomography, Optical CoherenceVascular Endothelial Growth Factor AAngiogenesis InhibitorsAntibodies, Monoclonal, HumanizedRanibizumabVascular Endothelial Growth Factor AVEGFA protein, humanDegenerationMaculaTreatment Medical

Identifiers

PMID25193672
PMCPMC4316940

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.